Law360, New York (July 13, 2012, 1:08 PM EDT) -- A California federal judge on Wednesday dismissed a proposed securities class action accusing Novartis AG subsidiary Genoptix Inc.'s executives of feathering their nests with company cash as sales figures tanked, ruling the firm's inaccurate revenue forecasts were forward-looking statements immune to litigation.
Investors spotlighted 80 allegedly deceptive statements by Genoptix’s top brass, but more than half were protected under the Private Securities Litigation Act’s safe-harbor provisions, U.S. District Judge Cathy Ann Bencivengo said.
Shareholders had argued that company leaders failed to make it clear that actual...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.